Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report

BACKGROUND: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab is a low-density lipoprotein (LDL)-lowering drug with a new mechanism, which is currently available in Japan. Here, for the first time, we report the successful use of the PCSK9 inhibitor in a patient with ref...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Nephrol
Main Authors: Awanami, Yuki, Fukuda, Makoto, Nonaka, Yasunori, Takashima, Tsuyoshi, Matsumoto, Keiichiro, Yamasaki, Masatora, Miyazono, Motoaki, Ikeda, Yuji
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5501341/
https://ncbi.nlm.nih.gov/pubmed/28683788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-017-0644-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados